Man Group plc Purchases Shares of 155,541 Keros Therapeutics, Inc. $KROS

Key Points

• Man Group plc acquired 155,541 shares of Keros Therapeutics during the second quarter, valued at approximately $1.66 million and representing about 0.78% of the company. Institutional investors collectively own 71.56% of Keros.
• Keros shares opened at $11.07, near the lower end of their 52-week range, while the company reported a quarterly loss of $1.45 per share—worse than analysts’ expected loss of $1.34.
• Analyst sentiment remains mixed, with four Buy, four Hold and one Sell rating; the consensus rating is Hold, with an average price target of $20.50 versus the current share price.

Man Group plc purchased a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 155,541 shares of the company's stock, valued at approximately $1,664,000. Man Group plc owned approximately 0.78% of Keros Therapeutics as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of KROS. The Manufacturers Life Insurance Company increased its stake in shares of Keros Therapeutics by 8.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company's stock valued at $166,000 after acquiring an additional 988 shares in the last quarter. UBS Group AG boosted its stake in Keros Therapeutics by 1.1% during the third quarter. UBS Group AG now owns 103,864 shares of the company's stock worth $1,643,000 after acquiring an additional 1,091 shares in the last quarter. Strs Ohio grew its holdings in Keros Therapeutics by 3.9% in the fourth quarter. Strs Ohio now owns 29,300 shares of the company's stock worth $597,000 after purchasing an additional 1,100 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company's stock worth $33,000 after purchasing an additional 1,166 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock valued at $42,000 after purchasing an additional 1,888 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Price Performance

NASDAQ:KROS opened at $11.07 on Wednesday. The firm has a 50-day moving average of $10.78 and a 200-day moving average of $11.48. The company has a market cap of $219.52 million, a PE ratio of -2.99 and a beta of 1.01. Keros Therapeutics, Inc. has a one year low of $9.69 and a one year high of $22.55.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. On average, equities research analysts expect that Keros Therapeutics, Inc. will post -5.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Alpna Seth sold 2,625 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the completion of the sale, the director directly owned 9,767 shares of the company's stock, valued at $104,702.24. This represents a 21.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Lorena Raquel Lerner sold 3,568 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the transaction, the insider owned 27,559 shares in the company, valued at $283,582.11. This represents a 11.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 13,768 shares of company stock valued at $144,979. 12.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on KROS shares. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Wells Fargo & Company decreased their target price on Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating for the company in a research report on Tuesday, August 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Wall Street Zen raised Keros Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Monday, August 24th. Finally, Leerink Partners decreased their price objective on Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating for the company in a report on Tuesday, August 4th. Four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $20.50.

About Keros Therapeutics

Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source